Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood–brain barrier disruption in newly diagnosed or recurrent glioblastoma: technical insights and clinical outcomes from a single-center experience
In our single-center experience, comprising the largest cohort of bevacizumab or cetuximab SIACI treatment for rGBM and ndGBM, this promising and cutting-edge intervention is highly feasible and safe.
Authors
- Christian Ferreira (ORCID: https://orcid.org/0009-0001-5325-1343)
- Faith Singh
- Tamika Wong
- John A. Boockvar (ORCID: https://orcid.org/0000-0002-8137-6303)
- David J. Langer (ORCID: https://orcid.org/0000-0001-6028-2765)
- Sanskruti Bokil
- Julianna Cavallaro
- Randy S. D’Amico (ORCID: https://orcid.org/0000-0002-3047-945X)
- Yafell Serulle (ORCID: https://orcid.org/0000-0002-7526-1868)
- Marcio Yuri Ferreira
- Sara Massimo
- Olivia Albers
Institutions
- Northwell Health (US)
- Lenox Hill Hospital (US)
Publication Details
- Journal
- Journal of NeuroInterventional Surgery
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1136/jnis-2025-023068
- Citations
- 4
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.50